

Certificate of Analysis

Cell Count	1.5 Million per vial
Viability	91%
CD4+	94.6%
CD25+ CD127-	84.7%
% Suppression at 1:8 Treg:Effector Ratio	91%
Sterility Testing	Negative for bacteria and fungi

Donor Information

Donor ID	287
Sex	Female
Age	49
Race	Caucasian
Height	5'7"
Weight	130
ABO Type	B Negative




HLA typing

	Allele 1	Allele 2
HLA-A	03:01	68:01
HLA-B	15:01	44:02
HLA-C	03:03	07:04
HLA-DRB1	15:01	01:01

Notes: Healthy CMV Donor, Allergies to Sulfa, Cipro, and cataflam.


Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1 and are negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

4951NV20



Co-Culture of Tregs Resulted in Suppression of Anti- CD3-mediated CD8+ T Cell Proliferation of Allogeneic Peripheral Blood Mononuclear Cells (PBMCs). In short, in a 96 well plate, 250,000 CFSE-labelled allogeneic responder PBMC were plated/well in the presence of 0.2 µg/mL anti-CD3 and varying number of Tregs at responder to Treg ratio shown in the chart above. The plate was incubated in a 37 deg C, 6% CO2 incubator. After 5 days of culture, individual wells were harvested and labelled with PE-labelled anti-CD8 mAb. Data was acquired on a flow cytometer and the extent of proliferation (Division Index, DI) was analyzed using FCS Express 4.0. % Suppression = $100 - (DI \text{ in the presence of Treg} / DI \text{ in the absence of Treg}) \times 100$.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.